ARA-290 10mg

ARA-290 (10mg) — About This Product

ARA-290 (also known as cibinetide or PH-BSP) is a synthetic peptide derived from erythropoietin (EPO), engineered to preserve tissue-protective and anti-inflammatory signaling without stimulating red blood cell production. In the scientific literature, ARA-290 has been investigated for its role in cellular protection, neuroinflammatory modulation, and nerve-related signaling pathways.

This peptide is supplied as a lyophilized powder in sterile, sealed vials and is intended strictly for laboratory research use. The 10 mg format supports controlled experimental applications, including formulation development, dose-ranging studies, and preclinical modeling. Researchers who buy ARA-290 typically do so for investigational work involving inflammation, neuropathic signaling, and tissue resilience.

• Amino Acid Sequence: ZEQLERALNSS (Z = pyroglutamic acid)
• Molecular Weight: 1,257.3 g/mol
• Molecular Formula: C₅₁H₈₄N₁₆O₂₁
• CAS Number: 1208243-50-8
• PubChem CID: 91810664
• Synonyms: cibinetide, PH-BSP
• Purity: ≥99%, verified by HPLC and mass spectrometry

ARA-290 is studied as a non-erythropoietic EPO-derived peptide, designed to activate protective cellular pathways while avoiding hematologic effects. Although research findings are ongoing, ARA-290 is not approved for clinical use and must remain limited to controlled laboratory settings.

• EPO-Derived Peptide: Engineered to isolate tissue-protective signaling
• Non-Erythropoietic Action: Does not increase red blood cell production in research models
• High Purity & Stability: Supplied as pharmaceutical-grade lyophilized powder
• Convenient Research Format: Sealed vials requiring reconstitution with sterile diluent
• Primary Research Areas: Inflammation modulation, neuropathic signaling, cellular stress response
• Multiple Model Systems: Studied in preclinical nerve, metabolic, and inflammatory models
• Regulatory Notice: Intended strictly for laboratory research only
• Ordering Information: Institutions that order ARA-290 should use it exclusively in approved research environments

ARA-290 is actively investigated for its selective interaction with the innate repair receptor (IRR), a heteromeric receptor complex composed of the erythropoietin receptor (EPOR) and the β-common receptor (CD131). By selectively binding to this EPOR–CD131 heterocomplex, ARA-290 activates tissue-protective and anti-inflammatory signaling without stimulating classical erythropoietic receptor homodimers.

Mechanistically, activation of the EPOR-CD131 complex initiates intracellular signaling cascades involving JAK2, PI3K-Akt, and NF-κB-associated pathways. Experimental data indicate modulation of macrophage cytokine secretion, attenuation of pro-inflammatory transcriptional programs, and regulation of apoptotic signaling under cellular stress conditions. Additionally, ARA-290 has been shown to antagonize TRPV1 (transient receptor potential vanilloid 1) channels in small nerve fibers, contributing to pain modulation and improved sensory thresholds.

Common Experimental Contexts

Due to these properties, laboratories that order ARA-290 frequently study it in the following research models:

• Endothelial cell culture assays examining vascular integrity
• Macrophage activation models investigating cytokine regulation
• Immune-cell signaling studies assessing pro-inflammatory pathway modulation
• Experimental colitis and immune-mediated tissue injury models
• Metabolic stress models evaluating cellular resilience
• Small-fiber nerve integrity studies and nociceptive pain investigations

Research endpoints commonly include inflammatory biomarker profiling, histological analysis, immune-cell phenotyping, and receptor-specific intracellular signaling readouts.

Published research has evaluated ARA-290 at microgram-level doses in animal and cellular models. Dosing strategies vary according to experimental design, delivery route, and study objectives.

Reported research observations include:

• Reduced inflammatory biomarkers
• Improved nerve signaling in neuropathic models
• No stimulation of erythropoiesis or red blood cell production

All findings are derived exclusively from preclinical and early investigational studies. There is currently no approved dosage and no established human safety profile.

o preserve peptide stability and integrity:

• Lyophilized Powder: Store at –20°C or lower, protected from light and moisture
• After Reconstitution: Store at 2–8°C and use within 10–14 days, according to protocol
• Handling Guidance: Avoid repeated freeze–thaw cycles, which may degrade peptide structure

Preclinical research has not reported hematologic toxicity. However, the human safety profile remains unestablished. This product is not approved for medical use and should be handled only in controlled research environments using appropriate institutional safety procedures.

References

https://pubmed.ncbi.nlm.nih.gov/28475703/

https://pmc.ncbi.nlm.nih.gov/articles/PMC3883966/

https://pmc.ncbi.nlm.nih.gov/articles/PMC5741312/

https://pubmed.ncbi.nlm.nih.gov/26774587/

https://www.pnas.org/doi/10.1073/pnas.0805594105

Compliance Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use.